MaxCyte Inc expected to post a loss of 11 cents a share - Earnings Preview

MaxCyte

05/05/2025 21:30

MaxCyte Inc MXCT.OQ MXCT.O is expected to show a fall in quarterly revenue when it reports  results on May 7 for the period ending March 31 2025

The Rockville Maryland-based  company is expected to report a 20.2% decrease in revenue to $9.055 million from $11.34 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.

‚ÄčLSEG's mean analyst estimate for MaxCyte Inc is for a loss of 11 cents per share.

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts had fallen by about 0.3% in the last three months. ‚Äč

Wall Street's median 12-month price target for MaxCyte Inc is $7.00‚Äč, above‚Äč its last closing price of $2.82. ‚Äč‚Äč‚Äč

Previous quarterly performance (using preferred earnings measure in US dollars). ‚Äč

QUARTER ENDING
STARMINESMARTESTIMATE¬ģ
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.11
-0.12
-0.10
Beat
18
Sep. 30 2024
-0.12
-0.12
-0.11
Beat
10.8
Jun. 30 2024
-0.13
-0.13
-0.09
Beat
28.9‚Äč
Mar. 31 2024
-0.13
-0.13
-0.09
Beat
30.8
‚Äč‚ÄčDec. 31 2023
-0.07
-0.07
-0.05
Beat
30.6
Sep. 30 2023
-0.10
-0.10
-0.11
Missed
-7.8‚Äč
Jun. 30 2023
-0.10
-0.10
-0.10
Met
-4.2
Mar. 31 2023
-0.11
-0.11
-0.11
Met
1.8

This summary was machine generated May 5 at 20:30 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)